CommercialPrior AuthMedium impact
Monoclonal Antibody Therapies for Migraine Prevention
Blue Cross & Blue Shield of Mississippi·MS · Neurology, Pain Management, Family Medicine +1 more·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBSMS updated their policy for CGRP monoclonal antibody migraine treatments (Aimovig, Emgality, Ajovy, Vyepti), requiring prior authorization with specific criteria including 4+ migraine days/month and failure of standard prophylactic treatments. Only Aimovig and Emgality are considered medically necessary for migraine prevention.
Action Required
Immediately: Update prior authorization workflows for CGRP monoclonal antibody therapies (Aimovig, Emgality, Ajovy, Vyepti). Billing team must verify formulary coverage through patient member ID searches before prescribing. Providers must document 4+ migraine days/month, failure of standard prophylactic therapies, consultation with headache specialist, and absence of medication overuse headache. Note that Ajovy and Vyepti are considered not medically necessary. Obtain prior auth before prescribing or claims will be denied.